Last edition
News about "Eli Lilly"
Eli Lilly has announced plans to invest USD 3 billion in a new manufacturing facility in Katwijk, the Netherlands, to expand its global capacity for producing oral medicines and strengthen its supply chain network.
Eli Lilly | 04/11/2025 | By Dineshwori
Eli Lilly to Pour USD 1.2B into Puerto Rico Facility Expansion Amid USA Manufacturing Push
Eli Lilly announced plans to invest more than USD 1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, as part of its broader initiative to enhance pharmaceutical production in the United States.
Eli Lilly | 03/11/2025 | By Darshana
Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India
Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.
Eli Lilly | 27/10/2025 | By Dineshwori | 135
Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes
Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.
Eli Lilly | 16/10/2025 | By Dineshwori | 141
Eli Lilly and Company has announced plans to invest more than USD 1 billion over the next several years to expand its contract manufacturing footprint in India, aimed at enhancing global access to its innovative medicines.
Eli Lilly | 07/10/2025 | By Darshana
Lilly Plans to Build USD 6.5 Billion Facility to Manufacture APIs in Texas
Eli Lilly will invest USD 6.5 billion to set up a new API manufacturing facility in Houston, Texas—its eighth US site since 2020—creating over 4,600 jobs and boosting domestic production of small molecule medicines.
Eli Lilly | 24/09/2025 | By Dineshwori | 110
AltrixBio Raises USD 5 Million Series A Financing and Appoints David Pass as CEO
Dr David Pass, a veteran of the pharma, biotech, and medical device sectors with a track record of scaling programs to over USD 1 billion in sales, succeeds AltrixBio Co-Founder and CEO Nancy Briefs, who led the company from inception and will now serve as Executive Chair.
Eli Lilly | 18/09/2025 | By Dineshwori | 124
Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results
Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.
Eli Lilly | 18/09/2025 | By Dineshwori | 176
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
Eli Lilly | 10/09/2025 | By Dineshwori
FDA tightens import controls on obesity drug ingredients amid safety concerns
The Food and Drug Administration (FDA) in the USA has intensified its scrutiny of imports containing GLP-1 drug ingredients, widely used in treatments for weight loss and diabetes, following increasing concerns over safety and quality.
Eli Lilly | 06/09/2025 | By Darshana | 287
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy